PUBLICATION

Novel Bacterial Auto-fluorescence Imaging Device Can Lead to more targeted debridement

Windy Cole, DPM; and Stacey Coe, BA, CCRP

Cole W and Coe S. Novel bacterial auto-fluorescence imaging device can lead to more targeted debridement. Today’s Wound Clinic. April 2019.

Access Article

Find out how to make a difference in wound care

MolecuLight Headquarters

425 University Avenue
Suite 700
Toronto, ON M5G 1T6
Canada

US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 209
Pittsburgh, PA 15203

T. +1 647-362-4684
North American Toll Free:
1-877-818-4360
F. +1 647-362-4730
E: info@moleculight.com

MolecuLight is a proud corporate member of:

© 2019 MolecuLight® Inc. All Rights Reserved.

The MolecuLight i:X™ Imaging Device is approved by Health Canada and has CE marking for sale in Canada and the European Union. The MolecuLight i:X™ Imaging Device has received FDA clearance. MolecuLight® and Look to Heal® are registered trademarks in Canada, the US and the EU.